Understanding LAMA2 muscle disease over time
Part of Bones, joints & muscles, Genetic & congenital clinical trials.
This study follows people with LAMA2-related muscular dystrophy (a genetic muscle-weakening condition) to learn how it changes over time and find better ways to measure it. By participating, you help researchers identify new disease markers that could improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have LAMA2-related muscular dystrophy confirmed by genetic testing or muscle biopsy showing no merosin protein.
- You must be able to visit the study site at least once a year for about 2 years.
- Adults can sign their own consent; parents or guardians must consent for children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a new protein that might help people with LAMA2-related muscular dystrophy. It uses stored samples to see if the protein could be a useful addition to future treatments.
This study follows people with LAMA2-related muscular dystrophy over time to better understand the condition. It may help with future treatments by learning more about how the disease progresses.
This study follows young children with LAMA2-related congenital muscular dystrophy to learn more about the disease. It does not test a new treatment, so it may help families understand the condition better and prepare for future trials.
This study follows children with LAMA2-related muscular dystrophy to learn how the condition changes over time. It does not test a new treatment, but helps researchers understand the disease better.
This trial collects health information from patients with certain inherited (genetic) muscle diseases and from their families. It may help researchers better understand the disease and improve care by learning what symptoms and treatments patients experience over time.
This study follows people with LAMA2-related muscular dystrophy or SELENON-related myopathy over 5 years to understand how the condition changes over time. It may help you by tracking your disease progression and contributing to future research.
Hear when a new Merosin Deficient CMD (Full or Partial) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.